CA184169
Laufzeit: 01.01.2012 - 31.12.2013
Kurzfassung
A randomized double-blind phase III study of ipilimumab administered at 3mg/kg vs at 10mg/kg in subjects with previously treated or untreated unresectable or metastatic melanoma
Laufzeit: 01.01.2012 - 31.12.2013
A randomized double-blind phase III study of ipilimumab administered at 3mg/kg vs at 10mg/kg in subjects with previously treated or untreated unresectable or metastatic melanoma
